Tapinarof cream for the topical treatment of plaque psoriasis in adults

References

• Lowes MA, Suárez-Fariñas M, Krueger JG. Immunology of psoriasis. Annu Rev Immunol. 2014;32(1):227–255. doi: 10.1146/annurev-immunol-032713-120225
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Mehta MD, Schupp CW, et al. Psoriasis prevalence in adults in the United States. JAMA Dermatol. 2021;157(8):940–946. doi: 10.1001/jamadermatol.2021.2007
   PubMed Web of Science ®Google Scholar
• Elmets CA, Korman NJ, Prater EF, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol. 2021;84(2):432–470. doi: 10.1016/j.jaad.2020.07.087
   PubMed Web of Science ®Google Scholar
• Griffiths CEM, Armstrong AW, Gudjonsson JE, et al. Psoriasis. Lancet. 2021;397(10281):1301–1315. doi: 10.1016/S0140-6736(20)32549-6
   PubMed Web of Science ®Google Scholar
• Murage MJ, Kern DM, Chang L, et al. Treatment patterns among patients with psoriasis using a large national payer database in the United States: a retrospective study. J Med Econ. 2018 Oct 25;22(1):1–9. doi: 10.1080/13696998.2018.1540424
   PubMed Web of Science ®Google Scholar
• Lebwohl MG, Stein Gold L, Strober B, et al. Phase 3 trials of tapinarof cream for plaque psoriasis. N Engl J Med. 2021;385(24):2219–2229. doi: 10.1056/NEJMoa2103629
   PubMed Web of Science ®Google Scholar
• Sekhon S, Jeon C, Nakamura M, et al. Review of the mechanism of action of coal tar in psoriasis. J DermatolTreat. 2018 May;29(3):230–232. Epub 2017 Sep 19. PMID: 28814117. doi: 10.1080/09546634.2017.1369494
   Google Scholar
• Alora-Palli MB, Perkins AC, Van Cott A, et al. Efficacy and tolerability of a cosmetically acceptable coal tar solution in the treatment of moderate plaque psoriasis: a controlled comparison with calcipotriene (calcipotriol) cream. Am J Clin Dermatol. 2010;11(4):275–283. doi: 10.2165/11530380-000000000-00000
   PubMed Web of Science ®Google Scholar
• Lebwohl MG, Kircik LH, Moore AY, et al. Effect of Roflumilast cream vs vehicle cream on chronic plaque psoriasis: the DERMIS-1 and DERMIS-2 randomized clinical trials. JAMA. 2022;328(11):1073–1084. doi: 10.1001/jama.2022.15632
   PubMed Web of Science ®Google Scholar
• Chiricozzi A, Pimpinelli N, Ricceri F, et al. Treatment of psoriasis with topical agents: recommendations from a Tuscany consensus. Dermatol Ther. 2017;30(6):e12549. doi: 10.1111/dth.12549
   Web of Science ®Google Scholar
• Alinia H, Moradi Tuchayi S, Smith JA, et al. Long-term adherence to topical psoriasis treatment can be abysmal: a 1-year randomized intervention study using objective electronic adherence monitoring. Br J Dermatol. 2017;176(3):759–764. doi: 10.1111/bjd.15085
   PubMed Web of Science ®Google Scholar
• Paller A, Hebert AA, Jett JE, et al. Tapinarof cream 1% Once daily for the treatment of extensive atopic dermatitis in adolescents and children: 4-week maximal-use trial. J Skin. 2022;6(6):s80. doi: 10.25251/skin.6.supp.80
   Google Scholar
• Yosipovitch G, Reaney M, Mastey V, et al. Peak Pruritus numerical rating scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis. Br J Dermatol. 2019;181(4):761–769. doi: 10.1111/bjd.17744
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Swensen AR, Nyirady J, et al. The psoriasis symptom diary: development and content validity of a novel patient-reported outcome instrument. Int J Dermatol. 2014;53(6):714–722. doi: 10.1111/j.1365-4632.2012.05798.x
   PubMed Web of Science ®Google Scholar
• Fernández-Gallego N, Sánchez-Madrid F, Cibrian D. Role of AHR ligands in skin homeostasis and cutaneous inflammation. Cells. 2021 Nov 15;10(11):3176. doi: 10.3390/cells10113176
   PubMed Web of Science ®Google Scholar
• Li J, Chen G, Wu H, et al. Identification of two pigments and a hydroxystilbene antibiotic from photorhabdus luminescens. Appl Environ Microbiol. 1995;61(12):4329–4333. doi: 10.1128/aem.61.12.4329-4333.1995
   PubMed Web of Science ®Google Scholar
• Dutky SR. Insect microbiology. Adv Appl Microbiol. 1959;1:175–200. doi: 10.1016/s0065-2164(08)70479-9
   PubMedGoogle Scholar
• Smith SH, Jayawickreme C, Rickard DJ, et al. Tapinarof is a Natural AhR agonist that resolves skin inflammation in mice and humans. J Invest Dermatol. 2017;137(10):2110–2119. doi: 10.1016/j.jid.2017.05.004
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Stein Gold L, Rubenstein DS, et al. Tapinarof in the treatment of psoriasis: a review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor-modulating agent. J Am Acad Dermatol. 2021;84(4):1059–1067. doi: 10.1016/j.jaad.2020.10.085
   PubMed Web of Science ®Google Scholar
• Shinde R, McGaha TL. The aryl hydrocarbon receptor: connecting immunity to the microenvironment. Trends Immunol. 2018;39(12):1005–1020. doi: 10.1016/j.it.2018.10.010
   PubMed Web of Science ®Google Scholar
• Uberoi A, Bartow-McKenney C, Zheng Q, et al. Commensal microbiota regulates skin barrier function and repair via signaling through the aryl hydrocarbon receptor. Cell Host Microbe. 2021;29(8):1235–1248.e8. doi: 10.1016/j.chom.2021.05.011
   PubMed Web of Science ®Google Scholar
• Sutter CH, Azim S, Wang A, et al. Ligand Activation of the Aryl Hydrocarbon Receptor Upregulates Epidermal Uridine Diphosphate Glucose Ceramide Glucosyltransferase and Glucosylceramides. J Invest Dermatol. 2023 Oct;143(10):1964–1972.e4. Epub 2023 Mar 31. PMID: 37004877; PMCID: PMC10529782. doi: 10.1016/j.jid.2023.03.1662
   PubMed Web of Science ®Google Scholar
• Jett JE, McLaughlin M, Lee MS, et al. Tapinarof cream 1% for extensive plaque psoriasis: a maximal use trial on safety, tolerability, and pharmacokinetics. Am J Clin Dermatol. 2022;23(1):83–91. doi: 10.1007/s40257-021-00641-4
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Vasist LS, Bullman JN, et al. Systemic pharmacokinetics, safety, and preliminary efficacy of topical AhR agonist tapinarof: results of a Phase 1 study. Clin Pharmacol Drug Dev. 2018;7(5):524–531. doi: 10.1002/cpdd.439
   PubMed Web of Science ®Google Scholar
• Stein Gold L, Bhatia N, Tallman AM, et al. A phase 2b, randomized clinical trial of tapinarof cream for the treatment of plaque psoriasis: secondary efficacy and patient- reported outcomes. J Am Acad Dermatol. 2021;84(3):624–631. doi: 10.1016/j.jaad.2020.04.181
   PubMed Web of Science ®Google Scholar
• Robbins K, Bissonnette R, Maeda-Chubachi T, et al. Phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of plaque psoriasis. J Am Acad Dermatol. 2019;80(3):714–721. doi: 10.1016/j.jaad.2018.10.037
   PubMed Web of Science ®Google Scholar
• Strober B, Stein Gold L, Bissonnette R, et al. One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: results from the PSOARING 3 trial. J Am Acad Dermatol. 2022;87(4):800–806. doi: 10.1016/j.jaad.2022.06.1171
   PubMed Web of Science ®Google Scholar
• Bagel J, Gold LS, Del Rosso J, et al. Tapinarof cream 1% once daily for the treatment of plaque psoriasis: patient-reported outcomes from the PSOARING 3 trial [published online ahead of print, 2023 May 10]. J Am Acad Dermatol. 2023;S0190-9622(23):00771–5. doi: 10.1016/j.jaad.2023.04.061
   Google Scholar
• Zhang J, Cai L, Zheng M. A novel topical treatment for plaque psoriasis: Benvitimod/tapinarof. J Am Acad Dermatol. 2022;86(3):e137–e138. doi: 10.1016/j.jaad.2021.10.053
   PubMed Web of Science ®Google Scholar
• Zhao L, Chen X, Cai L, et al. Randomized, double-blind, placebo-controlled, multiple-dose study of the safety, tolerability and pharmacokinetics of benvitimod, a candidate drug for the treatment of psoriasis. J Clin Pharm Ther. 2014;39(4):418–423. doi: 10.1111/jcpt.12158
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Bolduc C, Maari C, et al. Efficacy and safety of topical WBI-1001 in patients with mild to moderate psoriasis: results from a randomized double-blind placebo-controlled, phase II trial. J Eur Acad Dermatol Venereol. 2012;26(12):1516–1521. doi: 10.1111/j.1468-3083.2011.04332.x
   PubMed Web of Science ®Google Scholar
• Cai L, Chen GH, Lu QJ. et al. A double-blind, randomized, placebo- and positive-controlled phase III trial of 1% benvitimod cream in mild-to-moderate plaque psoriasis. Chin Med J (Engl). 2020 Nov 9];133(24):2905–2909. doi: 10.1097/CM9.0000000000001221
   PubMed Web of Science ®Google Scholar
• Roivant Sciences LTD. Quarterly report on form 10-Q. U.S. Securities and Exchange Commission; 2023 Aug 14. [cited 2023 Aug 20].
   Google Scholar
• Brouda I, Edison B, Van Cott A, et al. Tolerability and cosmetic acceptability of liquor carbonis distillate (coal tar) solution 15% as topical therapy for plaque psoriasis. Cutis. 2010;85(4):214–220.
   PubMed Web of Science ®Google Scholar
• Carroll CL, Feldman SR, Camacho FT, et al. Adherence to topical therapy decreases during the course of an 8-week psoriasis clinical trial: commonly used methods of measuring adherence to topical therapy overestimate actual use. J Am Acad Dermatol. 2004;51(2):212–216. doi: 10.1016/j.jaad.2004.01.052
   PubMed Web of Science ®Google Scholar
• Stein Gold L, Rubenstein DS, Peist K, et al. Tapinarof cream 1% once daily and benvitimod 1% twice daily are 2 distinct topical medications. J Am Acad Dermatol. 2021;85(3):e201–e202. doi: 10.1016/j.jaad.2021.04.103
   PubMed Web of Science ®Google Scholar
• VTAMA. Indications and usage dosage and Administration dosage forms … - VTAMA. [cited 2023 Aug 31]. Available from: www.Vtama.com/Pi/
   Google Scholar